Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a drug combo or therapy dogs ease PTSD?

NCT ID NCT07771530

Disease control Sponsor: University of Haifa Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 18, 2026 · Last updated Aug 19, 2026 · Updated 1 time

Summary

This trial tests two promising approaches for post-traumatic stress disorder (PTSD): a new combination of two existing drugs (reboxetine and methylphenidate) and dog-assisted therapy. Researchers will compare these against a placebo and occupational therapy in 160 adults with PTSD. The goal is to see which approach better reduces PTSD symptoms and to identify who might benefit most from each treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A combination of reboxetine and methylphenidate (Ritalin), compared with dog-assisted therapy, placebo, and occupational therapy.
What this could lead to
If successful, this could offer a new, more effective treatment option for PTSD, potentially combining medication with therapy to improve symptoms and quality of life.
What could go wrong
This is an early-stage trial, so the drug combination may not prove more effective than existing treatments, and both drugs carry potential side effects. Dog-assisted therapy may also not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 160 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * age between 18 and 70 years, * diagnosed with PTSD according to DSM-IV or DSM-5 criteria, * any psychotropic drug therapy that is being administered must be at a fixed dose for at least one month prior to the study initiation. Exclusion Criteria: * any health condition for which the use of reboxetine or methylphenidate is contraindicated, * comorbidity with major psychiatric disorder, * significant/active cardiovascular disease, * previous or current severe traumatic brain injury, * active substance dependency, * participating in another treatment program for PTSD of any kind.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Posttraumatic stress disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

post-traumatic stress disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Posttraumatic stress disorder PTSD

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Haifa

    RECRUITING

    Haifa, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.